BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17139647)

  • 1. Pulmonary sarcoidosis developing during infliximab therapy.
    O'Shea FD; Marras TK; Inman RD
    Arthritis Rheum; 2006 Dec; 55(6):978-81. PubMed ID: 17139647
    [No Abstract]   [Full Text] [Related]  

  • 2. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy.
    Izzi S; Francesconi F; Visca P; Altieri A; De Mutiis C; Trevisan G; Bonifati C
    Dermatol Online J; 2010 May; 16(5):16. PubMed ID: 20492833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab induced skin and pulmonary sarcoidosis in a rheumatoid arthritis patient.
    Josse S; Klemmer N; Moreno-Swirc S; Goëb V; Lequerré T; Vittecoq O
    Joint Bone Spine; 2009 Dec; 76(6):718-9. PubMed ID: 19464223
    [No Abstract]   [Full Text] [Related]  

  • 4. Sarcoidosis and tocilizumab: is there a link?
    Bustamente L; Buscot M; Marquette CH; Roux C
    Clin Exp Rheumatol; 2017; 35(4):716. PubMed ID: 28516883
    [No Abstract]   [Full Text] [Related]  

  • 5. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab.
    Almodóvar R; Izquierdo M; Zarco P; Javier Quirós F; Mazzucchelli R; Steen B
    Clin Exp Rheumatol; 2007; 25(1):99-101. PubMed ID: 17417999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of sarcoidosis during etanercept therapy.
    Ishiguro T; Takayanagi N; Kurashima K; Matsushita A; Harasawa K; Yoneda K; Tsuchiya N; Miyahara Y; Yamaguchi S; Yano R; Tokunaga D; Saito H; Ubukata M; Yanagisawa T; Sugita Y; Kawabata Y
    Intern Med; 2008; 47(11):1021-5. PubMed ID: 18520114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pulmonary and renal involvement in a TNFα antagonist drug-induced sarcoidosis].
    Olivier A; Gilson B; Lafontaine S; Pautot JX; Bindi P
    Rev Med Interne; 2012 May; 33(5):e25-7. PubMed ID: 21592629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
    Clementine RR; Lyman J; Zakem J; Mallepalli J; Lindsey S; Quinet R
    J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.
    Gifre L; Ruiz-Esquide V; Xaubet A; Gómez-Puerta JA; Hernández MV; Sanmartí R
    Arch Bronconeumol; 2011 Apr; 47(4):208-12. PubMed ID: 20638761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.
    Ostör AJ; Chilvers ER; Somerville MF; Lim AY; Lane SE; Crisp AJ; Scott DG
    J Rheumatol; 2006 Mar; 33(3):622-8. PubMed ID: 16511933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases.
    Scollard DM; Joyce MP; Gillis TP
    Clin Infect Dis; 2006 Jul; 43(2):e19-22. PubMed ID: 16779736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody.
    Mori S; Imamura F; Kiyofuji C; Sugimoto M
    Mod Rheumatol; 2006; 16(4):251-5. PubMed ID: 16906378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of pulmonary and cardiac sarcoidosis during etanercept therapy.
    Miyagi R; Ideguchi H; Soga T; Yamakawa Y; Otsuki H; Niino H; Shiina T; Ueda A; Ishigatsubo Y
    Int J Rheum Dis; 2014 Sep; 17(7):810-2. PubMed ID: 24460777
    [No Abstract]   [Full Text] [Related]  

  • 14. Comment on: Sarcoid-like granulomatosis in patients treated with tumour necrosis factor blockers: 10 cases.
    Massara A; Cavazzini L; La Corte R; Trotta F
    Rheumatology (Oxford); 2010 May; 49(5):1019-21; author reply 1021-2. PubMed ID: 20056768
    [No Abstract]   [Full Text] [Related]  

  • 15. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.
    Vandevyvere K; Luyten FP; Verschueren P; Lories R; Segaert S; Westhovens R
    Clin Rheumatol; 2007 Dec; 26(12):2205-2206. PubMed ID: 17876646
    [No Abstract]   [Full Text] [Related]  

  • 16. Polymyositis associated with infliximab treatment for rheumatoid arthritis.
    Urata Y; Wakai Y; Kowatari K; Nitobe T; Mizushima Y
    Mod Rheumatol; 2006; 16(6):410-1. PubMed ID: 17165006
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 20. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
    J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.